HERSHEY, PA–A compound that stimulates the production of a tumor-fighting protein may improve the usefulness of the protein in cancer therapy, according to a team of researchers.

TRAIL is a natural antitumor protein that suppresses tumor development during immune surveillance, the immune system’s process of patrolling the body for cancer cells. This process is lost during cancer progression, which leads to uncontrolled growth and spread of tumors.

The ability of TRAIL to initiate cell death selectively in cancer cells has led to ongoing clinical trials with artificially-created TRAIL or antibody proteins that mimic its action. Use of the TRAIL protein as a drug has shown that it is safe, but there have been some issues, including stability of the protein, cost of the drug, and the ability of the drug to distribute throughout the body and get into tumors, especially in the brain.

“The TRAIL pathway is a powerful way to suppress tumors but current approaches have limitations that we have been trying to overcome to unleash an effective and selective cancer therapy,” said Dr. Wafik El-Deiry, professor of medicine and chief of the hematology/oncology division, Penn State College of Medicine. “The TRAIL biochemical cell death pathway naturally lends itself as a drug target to restore anti-tumor immunity.”

Researchers have identified a compound called TRAIL-inducing Compound 10 (TIC10) as a potential solution. TIC10 stimulates the tumor suppression capabilities of TRAIL in both normal and tumor tissues, including in the brain, and induces tumor cell death in mice. They report their findings in the journal Science Translational Medicine.

TIC10 is a small molecule. This organic compound binds to a protein and alters what the protein does.

Stimulation of TRAIL protein is sustained in both tumor and normal cells, with the normal cells contributing to the TIC10-induced cancer cell death through a bystander effect. It is effective in cancer cell samples and cell lines resistant to conventional therapies.

“I was surprised and impressed that we were able to do this,” El-Deiry said. “Using a small molecule to significantly boost and overcome limitations of the TRAIL pathway appears to be a promising way to address difficult to treat cancers using a safe mechanism already used in those with a normal effective immune system. This candidate new drug, a first-in-its-class, shows activity against a broad range of tumor types in mice and appears safe at this stage.”

New treatments are needed for advanced cancer, as more than half a million people in the United States will die of cancer in 2013.

“We have enough preclinical information to support the rationale for testing this new drug in the clinic,” El-Deiry said.

TIC10 seems to be nontoxic to normal cells or mice even at doses 10 times higher that an observed therapeutic dose, however more research needs to be completed to satisfy FDA requirements prior to initiation of clinical testing.

Other researchers are Joshua E. Allen, David T. Dicker, Akshal S. Patel, Nathan G. Dolloff, Kimberly A. Scata, Wenge Wang, all of Penn State Hershey Cancer Institute; Gabriel Krigsfeld, Patrick A. Mayes, Luv Patel, University of Pennsylvania School of Medicine; Evangelos Messaris, Department of Surgery, Penn State College Medicine; Jun-Ying Zhou and Gen Sheng Wu, Wayne State University School of Medicine.

This study was funded by the American Cancer Society, Penn State Hershey Cancer Institute and the National Institutes of Health.

Located on the campus of Penn State Milton S. Hershey Medical Center in Hershey, Pa., Penn State College of Medicine boasts a portfolio of more than $106 million in funded research. Projects range from the development of artificial organs and advanced diagnostics to groundbreaking cancer treatments and understanding the fundamental causes of disease. Enrolling its first students in 1967, the College of Medicine has more than 1,600 students and trainees in medicine, nursing, the health professions and biomedical research on its campus.

(Philadelphia) -- New breast cancer research finds no increased risk of heart problems after certain types of breast cancer therapy. Smaller studies have previously raised concerns about heart damage when women with cancer opt for radiation treatments.

Cancer is the epidemic of modern times. Unlike other diseases that have plagued people throughout history like tuberculosis and polio, we haven’t yet discovered a vaccine against it. One of the most common manifestations of this disease is breast cancer, which affects not only one in eight women, but also thousands of men in the United States.

Dr. Shou Ling Leong, an educator at Penn State Hershey College of Medicine, explains that smoking cigarettes in the past was something that only men did, not women and children. But clever advertising campaigns targeted to women and children changed that.

Harrisburg, PA - October 9, 2012 - While the number of Pennsylvania women undergoing surgery for breast cancer at hospitals in the Commonwealth remained fairly constant over the past decade, the number of women who had both a mastectomy and a lumpectomy in the same year dropped significantly, according to new figures published today by the Pennsylvania Health Care Cost Containment Council (PHC4). The report also indicated that the number of women electing preventive surgery increased from 2002 to 2011. This latest PHC4 report is being released in conjunction with National Breast Cancer Awareness Month (October).

Harrisburg, PA – The Leukemia and Lymphoma Society (LLS) of Central Pennsylvania announced today that it will host a Town Hall Meeting open to the public.

October is National Breast Cancer Awareness Month. One doesn't have to look far to see a pink ribbon, buildings cast in pink light or fountains flowing with pink water. The color pink is associated with the cause so much during the month that everyone knows exactly what it signifies.

When the campaign began in October 1985, the focus was on early detection of breast cancer. That's still an important message, but billions of dollars have been donated and contributed toward breast cancer research and treatment.

Progress has been made. About 2% fewer breast cancers were detected between 1999 and 2005 and death rates from breast cancer have been dropping since 1990.

This episode of Radio Smart Talk explores the impact of National Breast Cancer Awareness Month in the past and into the future.

We'll also look into current statistics, treatments, research, and what the future holds.

Program guests include Pat Halpin-Murphy, the president and founder of the Pennsylvania Breast Cancer Coalition, Leigh Hurst, the founder of Feel Your Boobies, and Dr. Ronald Hempling, a gynecologic oncologist with WellSpan Health.

Listen to the program:

In the video below, Dr. Dennis Gingrich, an educator at Penn State Hershey College of Medicine, provides a brief history of smoking and the changes that have been made as a society to discourage smoking in public spaces.

Join us in our mission to remove access barriers to coordinated, quality care for cancer patients in Pennsylvania.

HARRISBURG, Pa. — You are invited to participate in this year’s “Fight for Air” Walk to help to raise awareness of lung disease and the need for better treatments and a cure. The walk will take place Sunday, October 14 at the Carousel Pavilion, Harrisburg City Island. Registration and fun begins at noon with the walk beginning at 1 p.m.